A prominent element of regulatory reform in the US and in Europe is the movement of OTC derivatives to centralized clearing. The use of clearinghouses has been advanced as a panacea; however, many questions remain to be answered. We will focus on the clearing requirements under the Dodd-Frank Act, issues raised in dealing with CCPs, and related questions for dealers and for end-users.
Speaker: David H. Kaufman
New York CLE credit is pending.